TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Mentalization-Based Group Therapy for Adolescents: A Pilot Randomised Controlled Trial
Brief Summary: This is a prospective parallel group design of group-based Mentalization-Based Therapy for Adolescents (MBT-A) through a pilot randomised controlled trial comparing group-based MBT-A plus treatment as usual (TAU) to TAU alone. As a pilot study, we aim to determine: the effectiveness of our recruitment strategies; compliance with protocol/procedures; trends towards reduced self-harm.


Options:
A: Arm Label: CAMS treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Psychotherapy | Arm Label: Treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psychotherapy | Intervention Type: BEHAVIORAL; Name: Psychotherapy; Assigned to Arm(s): CAMS treatment, Treatment as usual
B: Arm Label: Combined psychotherapy; Type: EXPERIMENTAL; Interventions: Behavioral: Combined psychotherapy | Arm Label: Outpatient individual psychotherapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Outpatient individual psychotherapy | Intervention Type: BEHAVIORAL; Name: Combined psychotherapy; Assigned to Arm(s): Combined psychotherapy | Intervention Type: BEHAVIORAL; Name: Outpatient individual psychotherapy; Assigned to Arm(s): Outpatient individual psychotherapy
C: Arm Label: dialectical behavior therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Dialectical behavior therapy | Arm Label: treatment as usual; Type: PLACEBO_COMPARATOR; Interventions: Other: Treatment as Usual: any other drug or psychotherapy offered to participants, except DBT | Arm Label: Receiving no treatment at all; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dialectical behavior therapy; Assigned to Arm(s): dialectical behavior therapy | Intervention Type: OTHER; Name: Treatment as Usual: any other drug or psychotherapy offered to participants, except DBT; Assigned to Arm(s): treatment as usual
D: Arm Label: MBT therapy plus treatment as usual; Type: EXPERIMENTAL; Interventions: Other: Mentalization-Based Group Therapy for Adolescents | Arm Label: Treatment as usual alone; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Mentalization-Based Group Therapy for Adolescents; Assigned to Arm(s): MBT therapy plus treatment as usual

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Seventy-two pregnant patients diagnosed of minor or intermediate beta thalassemia with mild anemia were randomly assigned to treatment group and control group. Patients in the treatment group were given 15 g of Colla corii asini in powder form daily for 4 weeks while the control group were observed and followed up in the same period without any treatments. Levels of hemoglobin(Hb), serum iron (SI), serum ferritin (SF) and three types of hemoglobin components \[adult hemoglobin (HbA), fetal hemoglobin (HbF), minor adult hemoglobin (HbA2)\] were measured before and after treatments.


Options:
A: Arm Label: thalidomide thalassemia; Type: EXPERIMENTAL; Interventions: Drug: Thalidomide | Intervention Type: DRUG; Name: Thalidomide; Assigned to Arm(s): thalidomide thalassemia
B: Arm Label: Hydroxyurea,blood transfusion; Type: ACTIVE_COMPARATOR; Interventions: Drug: hydroxyurea, blood transfusion | Arm Label: Hydroxyurea, Epiao; Type: EXPERIMENTAL; Interventions: Drug: Hydroxyurea ,Epiao | Intervention Type: DRUG; Name: Hydroxyurea ,Epiao; Assigned to Arm(s): Hydroxyurea, Epiao | Intervention Type: DRUG; Name: hydroxyurea, blood transfusion; Assigned to Arm(s): Hydroxyurea,blood transfusion
C: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Drug: Colla corii asini | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Colla corii asini; Assigned to Arm(s): Intervention group
D: Arm Label: thalidomide thalassemia; Type: EXPERIMENTAL; Interventions: Drug: Thalidomide | Intervention Type: DRUG; Name: Thalidomide; Assigned to Arm(s): thalidomide thalassemia

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Neurostimulation and Cognitive Intervention in Alzheimer's Disease
Brief Summary: This study is a double blind, sham-controlled clinical trial aiming to compare the long-term effects of stimulation in Alzheimer's Disease (AD). Sixty early AD patients will take part in a phase II/III clinical study over a 1-year period. The study involves transcranial direct current stimulation (tDCS), cognitive training (CT), detailed neuropsychological and neurological testing. These assessments will occur at baseline, then again at two month (end point). Those who achieve clinical improvement with neurostimulation and cognitive therapy will be invited to receive treatment for 12 months as part of a follow-up study.


Options:
A: Arm Label: Tailored Activity Program; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored Activity Program | Arm Label: Home Safety and Education Program; Type: ACTIVE_COMPARATOR; Interventions: Other: Home Safety and Education Program | Intervention Type: BEHAVIORAL; Name: Tailored Activity Program; Assigned to Arm(s): Tailored Activity Program | Intervention Type: OTHER; Name: Home Safety and Education Program; Assigned to Arm(s): Home Safety and Education Program
B: Intervention Type: BEHAVIORAL; Name: community occupational therapy in dementia; Assigned to Arm(s): N/A
C: Arm Label: active tDCS plus real CT; Type: EXPERIMENTAL; Interventions: Device: active tDCS, Behavioral: real CT | Arm Label: sham tDCS plus real CT; Type: EXPERIMENTAL; Interventions: Device: sham tDCS, Behavioral: real CT | Arm Label: active tDCS plus placebo CT; Type: EXPERIMENTAL; Interventions: Device: active tDCS, Behavioral: placebo CT | Arm Label: sham tDCS plus placebo CT; Type: PLACEBO_COMPARATOR; Interventions: Device: sham tDCS, Behavioral: placebo CT | Intervention Type: DEVICE; Name: active tDCS; Assigned to Arm(s): active tDCS plus placebo CT, active tDCS plus real CT | Intervention Type: DEVICE; Name: sham tDCS; Assigned to Arm(s): sham tDCS plus placebo CT, sham tDCS plus real CT | Intervention Type: BEHAVIORAL; Name: real CT; Assigned to Arm(s): active tDCS plus real CT, sham tDCS plus real CT | Intervention Type: BEHAVIORAL; Name: placebo CT; Assigned to Arm(s): active tDCS plus placebo CT, sham tDCS plus placebo CT
D: Arm Label: Intensive Protocol; Type: EXPERIMENTAL; Interventions: Behavioral: STOMP (Skill-building through Task-Oriented Motor Practice) | Arm Label: Less-Intensive Protocol; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: STOMP (Skill-building through Task-Oriented Motor Practice) | Intervention Type: BEHAVIORAL; Name: STOMP (Skill-building through Task-Oriented Motor Practice); Assigned to Arm(s): Intensive Protocol, Less-Intensive Protocol

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1 / 2 Single Arm Study of T-cells Expressing Anti-CD19 Chimeric Antigen Receptor in Pediatric and Young Adult Patients With B-cell Malignancies
Brief Summary: This phase 1 / 2 study will evaluate the response of B-cell malignancies expressing CD19 to autologous T cells transduced with a second generation anti-CD19 chimeric antigen receptor in children and young adults.


Options:
A: Arm Label: ACTR087, in combination with rituximab; Type: EXPERIMENTAL; Interventions: Biological: ACTR087, Biological: rituximab | Intervention Type: BIOLOGICAL; Name: ACTR087; Assigned to Arm(s): ACTR087, in combination with rituximab | Intervention Type: BIOLOGICAL; Name: rituximab; Assigned to Arm(s): ACTR087, in combination with rituximab
B: Arm Label: Single Arm; Type: EXPERIMENTAL; Interventions: Biological: CD19 CAR T cells | Intervention Type: BIOLOGICAL; Name: CD19 CAR T cells; Assigned to Arm(s): Single Arm
C: Arm Label: anti-CD19 and anti-CD20 dual specific CAR-T Cells; Type: EXPERIMENTAL; Interventions: Biological: Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells | Intervention Type: BIOLOGICAL; Name: Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells; Assigned to Arm(s): anti-CD19 and anti-CD20 dual specific CAR-T Cells
D: Arm Label: Phase 1 - Cohort 1A; Type: EXPERIMENTAL; Interventions: Biological: Patient Derived CD19 specific CAR T cells also expressing an EGFRt | Arm Label: Phase 1 - Cohort 1B; Type: EXPERIMENTAL; Interventions: Biological: Patient Derived CD19 specific CAR T cells also expressing an EGFRt | Arm Label: Phase 1 - Cohort 1C; Type: EXPERIMENTAL; Interventions: Biological: Patient Derived CD19 specific CAR T cells also expressing an EGFRt | Arm Label: Phase 1 - Cohort 1D; Type: EXPERIMENTAL; Interventions: Biological: Patient Derived CD19 specific CAR T cells also expressing an EGFRt | Arm Label: Phase 1 - Cohort 1F1; Type: EXPERIMENTAL; Interventions: Biological: Patient Derived CD19 specific CAR T cells also expressing an EGFRt | Arm Label: Phase 1 - Cohort 1F2; Type: EXPERIMENTAL; Interventions: Biological: Patient Derived CD19 specific CAR T cells also expressing an EGFRt | Arm Label: Phase 2; Type: EXPERIMENTAL; Interventions: Biological: Patient Derived CD19 specific CAR T cells also expressing an EGFRt | Intervention Type: BIOLOGICAL; Name: Patient Derived CD19 specific CAR T cells also expressing an EGFRt; Assigned to Arm(s): Phase 1 - Cohort 1A, Phase 1 - Cohort 1B, Phase 1 - Cohort 1C, Phase 1 - Cohort 1D, Phase 1 - Cohort 1F1, Phase 1 - Cohort 1F2, Phase 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Use of Home-monitoring and mHealth Systems to Predict Asthma Control and the Occurrence of Asthma Exacerbations
Brief Summary: The investigators will collect a range of physiological, behavioural and environmental data using current mHealth and home-monitoring systems, environmental databases and patient characteristics, to determine to what extent asthma control and the occurrence of asthma exacerbations can be predicted.


Options:
A: Arm Label: No intervention to DDS exposure - Asthma in Children; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention 1 - Asthma in Children; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention (1) for outdoor exposure reduction - Asthma in Children | Arm Label: Intervention 2 - Asthma in Children; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention (2) for outdoor and indoor exposure reduction - Asthma in Children | Arm Label: No intervention to DDS exposure - Atrial Fibrillation; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention 1 - Atrial Fibrillation; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention (1) for outdoor exposure reduction - Atrial Fibrillation | Arm Label: Intervention 2 - Atrial Fibrillation; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention (2) for outdoor and indoor exposure reduction - Atrial Fibrillation | Intervention Type: BEHAVIORAL; Name: Intervention (1) for outdoor exposure reduction - Asthma in Children; Assigned to Arm(s): Intervention 1 - Asthma in Children | Intervention Type: BEHAVIORAL; Name: Intervention (2) for outdoor and indoor exposure reduction - Asthma in Children; Assigned to Arm(s): Intervention 2 - Asthma in Children | Intervention Type: BEHAVIORAL; Name: Intervention (1) for outdoor exposure reduction - Atrial Fibrillation; Assigned to Arm(s): Intervention 1 - Atrial Fibrillation | Intervention Type: BEHAVIORAL; Name: Intervention (2) for outdoor and indoor exposure reduction - Atrial Fibrillation; Assigned to Arm(s): Intervention 2 - Atrial Fibrillation
B: Arm Label: Visit 1; Type: EXPERIMENTAL; Interventions: Device: No Face Mask | Arm Label: Visit 2; Type: EXPERIMENTAL; Interventions: Device: Face Mask | Intervention Type: DEVICE; Name: No Face Mask; Assigned to Arm(s): Visit 1 | Intervention Type: DEVICE; Name: Face Mask; Assigned to Arm(s): Visit 2
C: N/A
D: Arm Label: Salvational intervention(SI) group; Type: EXPERIMENTAL; Interventions: Drug: Budesonide/formoterol, Drug: tiotropium bromide | Arm Label: Control(CT) group; Type: ACTIVE_COMPARATOR; Interventions: Drug: tiotropium bromide | Intervention Type: DRUG; Name: Budesonide/formoterol; Assigned to Arm(s): Salvational intervention(SI) group | Intervention Type: DRUG; Name: tiotropium bromide; Assigned to Arm(s): Control(CT) group, Salvational intervention(SI) group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-407)
Brief Summary: This is a study of carboplatin and paclitaxel or nano particle albumin-bound paclitaxel (nab-paclitaxel) with or without pembrolizumab (MK-3475, KEYTRUDA®) in adults with first line metastatic squamous non-small cell lung cancer (NSCLC).

The primary hypotheses are that treatment with pembrolizumab prolongs: 1) Progression-free Survival (PFS) by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by a blinded central imaging vendor compared to placebo, and 2) Overall Survival (OS).

After analysis of interim results was conducted, the protocol was amended (Amendment 5) to allow participants the option to discontinue placebo in the control arm and to switch to pembrolizumab in the event of documented progressive disease as assessed by central review.


Options:
A: Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Pemetrexed, Drug: Carboplatin | Arm Label: Arm A:; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pemetrexed | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Arm A:, Arm B | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm B
B: Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): N/A
C: Arm Label: Pembrolizumab + Chemotherapy Combo; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab, Drug: Paclitaxel, Drug: Nab-paclitaxel, Drug: Carboplatin | Arm Label: Placebo + Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Nab-paclitaxel, Drug: Carboplatin, Drug: Saline placebo for pembrolizumab | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Pembrolizumab + Chemotherapy Combo | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Pembrolizumab + Chemotherapy Combo, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Nab-paclitaxel; Assigned to Arm(s): Pembrolizumab + Chemotherapy Combo, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Pembrolizumab + Chemotherapy Combo, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Saline placebo for pembrolizumab; Assigned to Arm(s): Placebo + Chemotherapy
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Docetaxel, Drug: Gemcitabine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Gemcitabine | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact Evaluation of Alive & Thrive's Multi-Sectoral Community-Based Approach to Improving Infant and Young Child Feeding in Amhara, Ethiopia
Brief Summary: Alive \& Thrive is an initiative that aims to scale up nutrition to save lives, prevent illness, and ensure healthy growth and development through improved infant young child feeding (IYCF) practices. The purpose of this study is to evaluate whether the Alive \& Thrive intervention package, consisting of interpersonal communication, community mobilization activities, and radio campaign, can increase complementary feeding practices (minimum dietary diversity and minimum meal frequency) while sustaining exclusive breastfeeding rate among children less than two years of age. The impact evaluation uses a cluster-randomized design where 20 geographic clusters (woredas/districts) were randomized to two study arms - 10 intervention areas and 10 comparison areas. Repeated cross-sectional baseline and endline surveys will be used to assess program impact.


Options:
A: Arm Label: A&T intervention areas; Type: EXPERIMENTAL; Interventions: Behavioral: A&T community-based interventions, Behavioral: Mass media | Arm Label: Comparison areas; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mass media | Intervention Type: BEHAVIORAL; Name: A&T community-based interventions; Assigned to Arm(s): A&T intervention areas | Intervention Type: BEHAVIORAL; Name: Mass media; Assigned to Arm(s): A&T intervention areas, Comparison areas
B: Intervention Type: BEHAVIORAL; Name: Maternal nutrition and infant feeding advice; Assigned to Arm(s): N/A
C: Arm Label: Nutrition messages; Type: EXPERIMENTAL; Interventions: Behavioral: SMS | Arm Label: General health messages; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: SMS | Intervention Type: BEHAVIORAL; Name: SMS; Assigned to Arm(s): General health messages, Nutrition messages
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Advice | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary Advice; Assigned to Arm(s): Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of Pegfilgrastim (Neulasta®) in Patients With Alcoholic Hepatitis
Brief Summary: This is a multi-center, prospective, randomized trial of standard of care vs. standard of care + pegfilgrastim (Neulasta®) among patients with a clinical diagnosis of alcoholic hepatitis and DF≥32.


Options:
A: Arm Label: prednisolone or pentoxifylline + pegfiltrastim; Type: EXPERIMENTAL; Interventions: Drug: Standard of care + pegfiltrastim | Arm Label: prednisolone or pentoxifylline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard of care | Intervention Type: DRUG; Name: Standard of care + pegfiltrastim; Assigned to Arm(s): prednisolone or pentoxifylline + pegfiltrastim | Intervention Type: DRUG; Name: Standard of care; Assigned to Arm(s): prednisolone or pentoxifylline
B: Arm Label: Standard Medical Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Medical Therapy | Arm Label: G-CSF + Standard Medical Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: G-CSF, Drug: Standard Medical Therapy | Intervention Type: DRUG; Name: G-CSF; Assigned to Arm(s): G-CSF + Standard Medical Therapy | Intervention Type: DRUG; Name: Standard Medical Therapy; Assigned to Arm(s): G-CSF + Standard Medical Therapy, Standard Medical Therapy
C: Arm Label: Granulocyte colony-stimulating factor; Type: EXPERIMENTAL; Interventions: Drug: Granulocyte colony-stimulating factor, Drug: standard treatment | Arm Label: standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: standard treatment | Intervention Type: DRUG; Name: Granulocyte colony-stimulating factor; Assigned to Arm(s): Granulocyte colony-stimulating factor | Intervention Type: DRUG; Name: standard treatment; Assigned to Arm(s): Granulocyte colony-stimulating factor, standard treatment
D: Arm Label: G-CSF + Erythropoietin; Type: EXPERIMENTAL; Interventions: Drug: G-CSF | Arm Label: G-CSF; Type: ACTIVE_COMPARATOR; Interventions: Drug: G-CSF+Erythropoetin | Intervention Type: DRUG; Name: G-CSF+Erythropoetin; Assigned to Arm(s): G-CSF | Intervention Type: DRUG; Name: G-CSF; Assigned to Arm(s): G-CSF + Erythropoietin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Comparison of Oral Misoprostol and Vaginal Misoprostol for Cervical Ripening and Induction of Labor
Brief Summary: The purpose of this study is to study if misoprostol administered orally is at least as effective as misoprostol administered vaginally for cervical ripening and the induction of labor. The main purpose is to show that oral misoprostol administration is non-inferior to vaginal misoprostol administration with respect to the time interval from misoprostol administration to onset of active phase of labor. The study is a non-inferiority, prospective randomized controlled trial comparing oral misoprostol given as 25 mcg every 2 hours versus vaginal misoprostol given as 25 mcg every 4 hours.


Options:
A: Arm Label: Oral Titrated Misoprostol Solution; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: Vaginal Misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Oral Titrated Misoprostol Solution | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Vaginal Misoprostol
B: Arm Label: conventional oral misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Arm Label: titrated oral misoprostol; Type: EXPERIMENTAL; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): conventional oral misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): titrated oral misoprostol
C: Arm Label: Oral misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Vaginal misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Oral misoprostol, Vaginal misoprostol
D: Arm Label: misoprostol/placebo using buccal; Type: PLACEBO_COMPARATOR; Interventions: Drug: misoprostol/placebo | Arm Label: misoprostol/placebo using vaginal; Type: PLACEBO_COMPARATOR; Interventions: Drug: misoprostol/placebo | Intervention Type: DRUG; Name: misoprostol/placebo; Assigned to Arm(s): misoprostol/placebo using buccal, misoprostol/placebo using vaginal

Answer: C